LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB:HEMA) announced today that the Company generated third quarter revenue of $7.3 million and a net loss of $621,000, or $0.06/share, compared to third quarter 2009 revenue of $8.4 million and net income of $233,000, or $0.02/share. The three month loss included $321,000 in expenses related to the closure of an unprofitable facility in Maine and the write off of impaired assets. The Company generated $23.2 million of revenue for the first nine months of 2010, with a net loss of $601,000 or $0.06/share, compared to $28.1 million in revenue for the same period in 2009, with $660,000 in net income or $0.07/share. The nine month 2010 net loss included $321,000 in expenses related to the closure of an unprofitable facility in Maine, the write off of impaired assets, and $184,000 in severance expenses paid to the Company’s former Chief Executive Officer and Chief Financial Officer in the first quarter.
“Nationwide pricing pressures affecting our Blood Products business intensified throughout the third quarter, more than offsetting growth in our Therapeutic Services business and obscuring continued progress in our corporate streamlining efforts,” said Pete van der Wal, HemaCare’s CEO. “Nonetheless, we were able to maintain our strong cash position in excess of $2.1 million with no debt. We have implemented further improvements in our cost structure which have already had a favorable impact on the current quarter’s results to date, and are increasing focus on our more profitable lines of business. We expect these efforts to result in improved bottom-line results.”
Also, HemaCare’s Board of Directors approved the expansion and extension of the Company’s existing share repurchase program. This action authorizes the Company to purchase a total of up to 2 million shares, compared to the prior authorization of up to 1 million shares, and extends the share repurchase program through December 31, 2011. To date, the Company has purchased 510,000 shares under the share repurchase program.
ABOUT HEMACARE CORPORATION
Founded in 1978, HemaCare collects, processes, and distributes blood products to hospital and research related organizations, provides cellular collection and other blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments to patients with a variety of disorders. HemaCare is licensed by the FDA and accredited by the AABB.
This press release also contains “forward-looking statements” under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words “anticipates,” “expects,” “intends,” “plans” and similar expressions. The forward-looking statements in this press release include statements that HemaCare expects its cost cutting efforts and increased focus on more profitable lines of business to result in improved bottom line results. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation, the following: a reduction in operating margins occasioned by costs increasing more rapidly than market prices, the reduced demand for blood products, declining blood donations, the loss of customers or the inability to pass on cost increases due to increased competition, an increase in operating costs due to changes in industry regulations and standards, a decrease in reimbursement rates; our competitive position may decline due to the potential adverse effect from changes in the healthcare industry, including consolidations, which could affect access to customers, our inability to attract, retain and motivate management and other skilled employees, an increased emphasis by our competitors on customer service may diminish the advantages we enjoy from our service-focused operations, and our competitors’ not-for-profit status gives them advantages in acquiring customers; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
|Condensed Consolidated Data|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Statements of Income:|
|General and administrative expenses||$||1,285,000||$||1,295,000||$||4,056,000||$||4,368,000|
|(Loss) income before income taxes and discontinued operations||($678,000||)||$||158,000||($624,000||)||$||659,000|
|Benefit from income taxes||($70,000||)||($88,000||)||($60,000||)||($38,000||)|
|Net (loss) income before discontinued operations||($608,000||)||$||246,000||($564,000||)||$||697,000|
|Loss from discontinued operations, net of tax||($13,000||)||($13,000||)||($37,000||)||($37,000||)|
|Net (loss) income||($621,000||)||$||233,000||($601,000||)||$||660,000|
|Basic and diluted (loss) earnings per share||($0.06||)||$||0.02||($0.06||)||$||0.07|
|Weighted average shares outstanding – basic||10,064,000||10,050,000||10,054,000||9,994,000|
|Weighted average shares outstanding – diluted||10,064,000||10,257,000||10,054,000||10,086,000|
|Cash and cash equivalents||$||2,151,000||$||1,007,000|
|Other current assets||4,815,000||5,368,000|
Liabilities and Shareholders’ Equity
Total liabilities and shareholders’ equity